| Q81433325 | Antiretroviral-associated Hepatotoxicity |
| Q36508979 | Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women |
| Q55263551 | Clinical and genetic determinants of nevirapine plasma trough concentration. |
| Q33602047 | Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. |
| Q34566233 | Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients |
| Q38851687 | Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets |
| Q51202282 | Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions. |
| Q40218681 | Drug hypersensitivity reactions in patients with HIV disease |
| Q37644125 | HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play? |
| Q36718901 | Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. |
| Q36903921 | Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis |
| Q36422444 | Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women |
| Q36738171 | Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review |
| Q33861048 | Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis. |
| Q46923095 | Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine |
| Q36331864 | Sex differences in antiretroviral therapy-associated intolerance and adverse events |
| Q46345016 | Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy |